Skip to Content

'
Laurence James Neil Cooper, M.D., Ph.D.

Present Title & Affiliation

Primary Appointment

Professor (Tenured), Department of Pediatrics Patient Care, Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX
Grant Taylor, W. W. Sutow and Margaret Sullivan Distinguished Professor, Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX
Director, Immunology Laboratory of Physician Scientists, Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX
Section Chief, Cell Therapy, Children's Cancer Hospital, The University of Texas MD Anderson Cancer Center, Houston, TX
Associate Director, Center for Cancer Immunology Research, Department of Immunology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Professor, Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX

Bio Statement

Dr. Laurence J.N. Cooper obtained his M.D. and Ph.D. degrees at Case Western Reserve University in Cleveland and then training in Pediatric Oncology and Bone Marrow Transplantation (BMT) at the Fred Hutchinson cancer Research Center in Seattle. He joined M.D. Anderson Cancer Center in 2006 and currently leads the Pediatric Cell Therapy service (formally named the BMT program). In addition to caring for children, adolescents and young adults undergoing autologous and allogeneic hematopoietic stem-cell transplantation (HSCT), he runs a laboratory translating immunology into clinical practice. His program has multiple investigator-initiated trials that infuse T cells and NK cells to target malignancies. The adoptive transfer of lymphocytes represents the future of HSCT as he and other investigators enhance the potency of the immune system to eliminate residual cancers.

University of Texas Graduate School of Biomedical Sciences website: http://gsbs.uth.tmc.edu/tutorial/cooper.html

Education & Training

Degree-Granting Education

1994 Case Western Reserve University, Cleveland, OH, MD, Medical
1993 Case Western Reserve University, Cleveland, OH, PHD, Immunology
1986 Kenyon College, Gambier, OH, BA, Biology

Postgraduate Training

7/1996-6/1999 Pediatric Hematology-Oncology Fellowship, Pediatric Hematology-Oncology Fellowship, University of Washington, Fred Hutchinson Cancer Research Center, Seattle, WA, Irv Bernstein
7/1996-6/1999 Post-Doctoral Training, Immunology, University of Washington, Fred Hutchinson Cancer Research Center, Seattle, WA, Phil Greenburg
6/1994-7/1996 Pediatric Resident, Pediatric Resident, University of Washington, Children’s Hospital and Regional Medical Center, Seattle, WA, Richard Sugarman

Board Certifications

6/2013 Pediatric Hematology Oncology
12/2012 American Board of Pediatrics

Experience/Service

Academic Appointments

Associate Professor, Department of Pediatrics Patient Care, Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX, 12/2005-8/2011
Associate Professor, Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, 12/2005-8/2011
Assistant Professor, Pediatric Hematology/Oncology, City of Hope National Medical Center, Duarte, CA, 1/2001-1/2005
Assistant Professor, Beckman Research Institute, Duarte, CA, 1/2001-1/2005
Acting Pediatrics Instructor and Research Associate, Division of Pediatrics, University of Washington, Seattle, WA, 1/1999-1/2001

Other Appointments/Responsibilities

External Advisory Board Member, North Dakota State University, Fargo, ND, 8/2011-present
K21 Adjunct Member, The Ken Kennedy Institute for Information Technology, Rice University, Houston, TX, 6/2011-present
Peer Reviewer, Pediatrics Comparative Effectiveness Review (CER), Blue Cross and Blue Shield Association - Technology Evaluation Center, Chicago, IL, 3/2011-present
MDACC Lead, Cancer Immunotherapy Trials Network (CITN), Houston, TX, 2/2011-present
Committee Member, Blue Cross and Blue Shield Association - Technology Evaluation Center, Houston, TX, 2009-present
Member, University of Arkansas for Medical Sciences, P01 Advisory Board, Little Rock, AR, 2009-present

Consultantships

Advisor, Novo Nordisk, Inc, Princeton, NJ, 2007
Advisor, Xolair Pediatric Oncology Advisory Board, Florham Park, NJ, 2007

Institutional Committee Activities

Chair, Research Laboratory Space Subcommittee of Research Council, 9/2012
Chair, Clinical Research Committee, 9/2012
Appointed Member, Select Agent Policy Committee (SEPC), 1/2012-present
Member, Cancer Center Support Group (CCSG) Internal Advisory Board for the Flow Cytometry/Confocal Microscopy Core, 10/2011-present
Co-Leader, Cancer Center Support Group (CCSG) Immunology Program, 9/2011-present
Member, Technology Review Committee (TRC), 9/2011-present
Member, Investigational Cancer Therapeutics MS/PhD Steering Committee, 8/2011-present
Member, Immunology Department Chair Search Committee, 7/2011-present
Member, Embryonic and Induced Pluripotent Stem Cell Research Oversight (EIPSCRO) Committee, 7/2011-present
Member, Strategic Assessment of Clinical Programs Steering Committee, 6/2011-present
Chair-Elect, Postdoctoral Advisory Committee, 5/2011-9/2011
Council Member, Research Laboratory Space Subcommittee of the Research Council, 2/2010-present
Member, Immune Monitoring Core Laboratory (IMCL) Advisory Board, Cancer Center Support Group (CCSG), 2009-present
Member, Multidisciplinary Research Advisory Committee, 2009-2012
Faculty, Faculty Strategic Planning Research Retreat, 2009
Member, Steering Committee, Institute for Personalized Cancer Therapy (IPCT), 2008-present
Committee Member, Office of Research Administration and Operations Advisory Group, 7/2007-present
Member, Flow Cytometry & Cellular Imaging Core Facility Users Committee, 2007
Member, GMP Steering Committee, 2006

Honors and Awards

2012-2013 Men of Distinction Award, Men of Distinction
2012 Robert M. Chamberlain Distinguished Mentor Award, MD Anderson Cancer Center
2010 Best Boss Award, The University of Texas M.D. Anderson Cancer Center
2009-present Faculty Scholar Awards, The University of Texas M. D. Anderson Cancer Center
2008-present Clinical Scientist Award in Translational Research, Burroughs Wellcome Fund
2007 Induction into the American Society for Clinical Investigation
2004 American Society of Gene Therapy Young Investigator Award, ASGT
2002-2004 Scholar, Sidney Kimmel Foundation for Cancer Research
1999-2002 Leukemia Society of America Fellow, Leukemia and Lymphoma Society
1999-2001 Scholar Award, NIH Child Health Research Center
1999 E. Donnall Thomas Fellowship
1999 Young Investigator Award, American Society of Clinical Oncology
1994 The Henry F. Sanders' Award in Pediatrics, Case Western Reserve University
1987-1994 Medical Scientist Training Program Pre-Doctoral Fellowship, NIH
1986 Phi Beta Kapa

Professional Memberships

American Society for Blood and Marrow Transplantation, Arlington Heights, IL
Member, 2006-present
American Society for Blood and Marrow Transplantation
Organizing Committee Member, 2006-present
American Society for Blood and Marrow Transplantation on Cellular Therapies
Coordinating Committee Task Force, 7/2010-present
American Society of Gene & Cell Therapy
Board of Directors-Elect, 12/2011-present
American Society of Gene & Cell Therapy, Cancer Gene Therapy Committee
Chair, 2009-2010
American Society of Gene & Cell Therapy, Cancer Gene Therapy Committee
Committee Member, 2004-present
American Society of Hematology
Member, 2006-present
American Society of Pediatric Hematology / Oncology
Member, 2006-present
Blood and Marrow Transplant Steering Committee, Houston, TX
Member, 7/2007-present
California Medical Association, Los Angeles, CA
Member, 2002-present
Cellular Therapeutics SG, Vancouver, Canada
Vice Chair, 2007-present
Center for International Blood and Marrow Transplant Research (CIBMTR)
Co-Chair nomination of Pediatric Cancer Committee, 10/2008-present
Dana-Farber/Harvard Cancer Center, Boston
ad hoc member External Advisory Board, 10/2010-present
Harris County Medical Society, Houston, TX
Member, 2006-present
International Society for Biological Therapy of Cancer (ISCT)
Committee Member, 2005-present
International Society for Cellular Therapy (ISCT) Immunotherapy Committee, Vancouver, British Columbia, Canada
Committee Member, 2007-present
Lymphoma Research Foundation
Follicular Lymphoma Consortium member, 2008-present
National Cancer Institute, Pediatric Oncology Branch Steering Committee
Steering Committee, 10/2008-present
The American Society for Clinical Investigation, Ann Arbor, MI
ASCI Nomination Committee, 9/2009-present
The University of Texas Graduate School of Biomedical Sciences at Houston, Houston, TX
Member, 9/2010-8/2011
Un Ponte per Houston (A Bridge to Houston) to assist patients coming from Italy to The University of Texas M.D. Anderson Cancer Center, Houston
Medical Director, 2010-present

Selected Publications

Peer-Reviewed Original Research Articles

1. Torikai H, Reik A, Soldner F, Warren EH, Yuen C, Zhou Y, Crossland DL, Huls H, Littman N, Zhang Z, Tykodi SS, Kebriaei P, Lee DA, Miller JC, Rebar EJ, Holmes MC, Jaenisch R, Champlin RE, Gregory PD, Cooper LJ. Towards eliminating HLA class I expression to generate universal cells from allogeneic donors. Blood. e-Pub 6/2013. PMID: 23741009.
2. Knorr DA, Ni Z, Hermanson D, Hexum MK, Bendzick L, Cooper LJ, Lee DA, Kaufman DS. Clinical-Scale Derivation of Natural Killer Cells From Human Pluripotent Stem Cells for Cancer Therapy. Stem Cells Transl Med. e-Pub 3/2013. PMID: 23515118.
3. Liu Y, Wu HW, Sheard MA, Sposto R, Somanchi SS, Cooper LJ, Lee DA, Seeger RC. Growth and Activation of Natural Killer Cells Ex Vivo from Children with Neuroblastoma for Adoptive Cell Therapy. Clin Cancer Res. e-Pub 2/2013. PMID: 23378384.
4. Maiti SN, Huls H, Singh H, Dawson M, Figliola M, Olivares S, Rao P, Zhao YJ, Multani A, Yang G, Zhang L, Crossland D, Ang S, Torikai H, Rabinovich B, Lee DA, Kebriaei P, Hackett P, Champlin RE, Cooper LJ. Sleeping beauty system to redirect T-cell specificity for human applications. J Immunother 36(2):112-23, 2/2013. PMCID: PMC3568214.
5. Deniger DC, Switzer K, Mi T, Maiti S, Hurton L, Singh H, Huls H, Olivares S, Lee DA, Champlin RE, Cooper LJ. Bispecific T-cells Expressing Polyclonal Repertoire of Endogenous γδ T-cell Receptors and Introduced CD19-specific Chimeric Antigen Receptor. Mol Ther. e-Pub 1/2013. PMID: 23295945.
6. Hackett PB, Largaespada DA, Switzer KC, Cooper LJ. Evaluating risks of insertional mutagenesis by DNA transposons in gene therapy. Transl Res. e-Pub 1/2013. PMID: 23313630.
7. Huls MH, Figliola MJ, Dawson MJ, Olivares S, Kebriaei P, Shpall EJ, Champlin RE, Singh H, Cooper LJ. Clinical application of sleeping beauty and artificial antigen presenting cells to genetically modify T cells from peripheral and umbilical cord blood. J Vis Exp(72), 2013. e-Pub 2/2013. PMID: 23407473.
8. Singh H, Figliola MJ, Dawson MJ, Olivares S, Zhang L, Yang G, Maiti S, Manuri P, Senyukov V, Jena B, Kebriaei P, Champlin RE, Huls H, Cooper LJ. Manufacture of Clinical-Grade CD19-Specific T Cells Stably Expressing Chimeric Antigen Receptor Using Sleeping Beauty System and Artificial Antigen Presenting Cells. PLoS One 8(5):e64138, 2013. e-Pub 5/2013. PMID: 23741305.
9. Liadi I, Roszik J, Romain G, Cooper LJ, Varadarajan N. Quantitative High-throughput Single-cell Cytotoxicity Assay For T Cells. J Vis Exp(72), 2013. e-Pub 2/2013. PMID: 23407457.
10. Hosing C, Kebriaei P, Wierda W, Jena B, Cooper LJ, Shpall E. CARs in Chronic Lymphocytic Leukemia - Ready to Drive. Curr Hematol Malig Rep. e-Pub 12/2012. PMID: 23225251.
11. de Lima M, McNiece I, Robinson SN, Munsell M, Eapen M, Horowitz M, Alousi A, Saliba R, McMannis JD, Kaur I, Kebriaei P, Parmar S, Popat U, Hosing C, Champlin R, Bollard C, Molldrem JJ, Jones RB, Nieto Y, Andersson BS, Shah N, Oran B, Cooper LJ, Worth L, Qazilbash MH, Korbling M, Rondon G, Ciurea S, Bosque D, Maewal I, Simmons PJ, Shpall EJ. Cord-blood engraftment with ex vivo mesenchymal-cell coculture. N Engl J Med 367(24):2305-15, 12/2012. PMID: 23234514.
12. Bhatnagar P, Li Z, Choi Y, Guo J, Li F, Lee DY, Figliola M, Huls H, Lee DA, Zal T, Li KC, Cooper LJ. Imaging of genetically engineered T cells by PET using gold nanoparticles complexed to Copper-64. Integr Biol (Camb). e-Pub 10/2012. PMID: 23034721.
13. Zhang M, Maiti S, Bernatchez C, Huls H, Rabinovich B, Champlin RE, Vence LM, Hwu P, Radvanyi L, Cooper LJ. A New Approach to Simultaneously Quantify Both TCR α- and β-Chain Diversity after Adoptive Immunotherapy. Clin Cancer Res. e-Pub 8/2012. PMID: 22761473.
14. Somanchi SS, Somanchi A, Cooper LJ, Lee DA. Engineering lymph node homing of ex vivo expanded human natural killer cells via trogocytosis of the chemokine receptor CCR7. Blood. e-Pub 4/12/2012. PMID: 22498742.
15. Huang G, Yu L, Cooper LJ, Hollomon M, Huls H, Kleinerman ES. Genetically Modified T Cells Targeting Interleukin-11 Receptor a-Chain Kill Human Osteosarcoma Cells and Induce the Regression of Established Osteosarcoma Lung Metastases. Cancer Res 72(1):271-81, 1/2012. e-Pub 11/2011. PMID: 22075555.
16. Kebriaei P, Huls H, Jena B, Munsell M, Jackson R, Lee DA, Hackett PB, Rondon G, Shpall E, Champlin RE, Cooper LJ. Infusing CD19-directed T cells to augment disease control in patients undergoing autologous hematopoietic stem-cell transplantation for advanced B-lymphoid malignancies. Hum Gene Ther. e-Pub 1/2012. PMID: 22107246.
17. O'Connor CM, Sheppard S, Hartline CA, Huls H, Johnson M, Palla SL, Maiti S, Ma W, Davis RE, Craig S, Lee DA, Champlin R, Wilson H, Cooper LJ. Adoptive T-Cell Therapy Improves Treatment of Canine Non -Hodgkin Lymphoma Post Chemotherapy. Sci Rep 2:249, 2012. e-Pub 2/2012. PMCID: PMC3278154.
18. Ji Y, Feng L, Liu P, Shpall EJ, Kebriaei P, Champlin R, Berry D, Cooper LJ. Bayesian continual reassessment method for dose-finding trials infusing T cells with limited sample size. J Biopharm Stat 22(6):1206-19, 2012. PMCID: PMC3501341.
19. Kebriaei P, Kelly SS, Manuri P, Jena B, Jackson R, Shpall E, Champlin R, Cooper LJ. Chimeric Antibody Receptors (CARs): Driving T-Cell Specificity to Enhance Antitumor Immunity. Front Biosci (Schol Ed) 4:520-531, 2012. e-Pub 1/2012. PMID: 22202074.
20. Denman CJ, Senyukov VV, Somanchi SS, Phatarpekar PV, Kopp LM, Johnson JL, Singh H, Hurton L, Maiti SN, Huls MH, Champlin RE, Cooper LJ, Lee DA. Membrane-bound IL-21 promotes sustained ex vivo proliferation of human natural killer cells. PLoS One 7(1):e30264, 2012. e-Pub 1/2012. PMCID: PMC3261192.
21. Roszik J, Rabinovich B, Cooper LJ. Imaging of T cells expressing chimeric antigen receptors. Immunotherapy 3(12):1411-4, 12/2011. PMID: 22091674.
22. Hackett PB, Aronovich EL, Hunter D, Urness M, Bell JB, Kass SJ, Cooper LJ, McIvor S. Efficacy and Safety of Sleeping Beauty Transposon-Mediated Gene Transfer in Preclinical Animal Studies. Curr Gene Ther 11(5):341-9, 10/2011. e-Pub 8/2011. PMID: 21888621.
23. Capitini CM, Gottschalk S, Brenner M, Cooper LJ, Handgretinger R, Mackall CL. Highlights of the Second International Conference on “Immunotherapy in Pediatric Oncology”. Pediatr Hematol Oncol 28(6):459-60, 9/2011. PMID: 21854215.
24. Jin Z, Maiti S, Huls H, Singh H, Olivares S, Mátés L, Izsvák Z, Ivics Z, Lee DA, Champlin RE, Cooper LJ. The hyperactive Sleeping Beauty transposase SB100X improves the genetic modification of T cells to express a chimeric antigen receptor. Gene Ther 18(9):849-56, 9/2011. e-Pub 3/31/2011. PMID: 21451576.
25. Lacey SF, La Rosa C, Kaltcheva T, Srivastava T, Seidel A, Zhou W, Rawal R, Hagen K, Krishnan A, Longmate J, Andersson HA, St John L, Bhatia R, Pullarkat V, Forman SJ, Cooper LJ, Molldrem J, Diamond DJ. Characterization of immunologic properties of a second HLA-A2 epitope from a granule protease in CML patients and HLA-A2 transgenic mice. Blood 118(8):2159-69, 8/25/2011. e-Pub 6/30/2011. PMCID: PMC3162352.
26. Izsvák Z, Hackett PB, Cooper LJ, Ivics Z. Translating Sleeping Beauty transposition into cellular therapies: Victories and challenges. Bioessays 33(6):478-9, 6/2011. PMID: 20652893.
27. Ertl HC, Zaia J, Rosenberg SA, June CH, Dotti G, Kahn J, Cooper LJ, Corrigan-Curay J, Strome SE. Considerations for the Clinical Application of Chimeric Antigen Receptor T Cells: Observations from a Recombinant DNA Advisory Committee Symposium, June 15, 2010. Cancer Res 71(9):3175-3181, 5/1/2011. PMID: 21531763.
28. Singh H, Figliola MJ, Dawson MJ, Huls H, Olivares S, Switzer K, Mi T, Maiti S, Kebriaei P, Lee DA, Champlin RE, Cooper LJ. Reprogramming CD19-Specific T Cells with IL-21 Signaling Can Improve Adoptive Immunotherapy of B-Lineage Malignancies. Cancer Res 71(10):3516-27, 5/15/2011. e-Pub 5/10/2011. PMCID: PMC3096697.
29. Bernatchez C, Zhu K, Li Y, Andersson H, Ionnides C, Fernandez-Vina M, Cano P, Cooper L, Abbruzzese J, Hwu P, Chang DZ, Radvanyi LG. Altered decamer and nonamer from an HLA-A0201-restricted epitope of Surviving differentially stimulate T-cell responses in different individuals. Vaccine 29(16):3021-30, 4/5/2011. e-Pub 2/12/2011. PMCID: PMC3070784.
30. Kohn DB, Dotti G, Brentjens R, Savoldo B, Jensen M, Cooper LJ, June CH, Rosenberg S, Sadelain M, Heslop HE. CARs on Track in the Clinic. Mol Ther 19(3):432-8, 3/2011. PMCID: PMC3048197.
31. Cooper LJ. Off-the-shelf T-cell therapy. Blood 116(23):474 1-3, 12/2010. PMID: 21127184.
32. Choi Y, Yuen C, Maiti SN, Olivares S, Gibbons H, Huls H, Raphael R, Killian TC, Stark DJ, Lee DA, Torikai H, Monticello D, Kelly SS, Kebriaei P, Champlin RE, Biswal SL, Cooper LJ. A high throughput microelectroporation device to introduce a chimeric antigen receptor to redirect the specificity of human T cells. Biomed Microdevices 12(5):855-63, 10/2010. PMID: 20574820.
33. Pulsipher MA, Horwitz EM, Haight AE, Kadota R, Chen AR, Frangoul H, Cooper LJ, Jacobsohn DA, Goyal RK, Mitchell D, Nieder ML, Yanik G, Cowan MJ, Soni S, Gardner S, Shenoy S, Taylor D, Cairo M, Schultz KR. Advancement of Pediatric Blood and Marrow Transplantation Research in North America: Priorities of the Pediatric Blood and Marrow Transplant Consortium. Biol Blood Marrow Transplant 16(9):1212-21, 9/2010. PMCID: PMC2891395.
34. Jensen MC, Popplewell L, Cooper LJ, DiGiusto D, Kalos M, Ostberg JR, Forman SJ. Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans. Biol Blood Marrow Transplant 16(9):1245-1256, 9/2010. PMID: 20304086.
35. Davies JK, Singh H, Huls H, Yuk D, Lee DA, Kebriaei P, Champlin RE, Nadler LM, Guinan EC, Cooper LJ. Combining CD19 redirection and alloanergization to generate tumor-specific human T cells for allogeneic cell therapy of B-cell malignancies. Cancer Res 70(10):3915-3924, 5/2010. PMID: 20424114.
36. Hurton LV, Siddik RI, Singh H, Olivares S, Rabinovich BA, Tian R, Mojsilovic D, Hildebrand W, Lee DA, Kelly SS, Champlin R, Shpall EJ, Fernandez-Vińa M, Cooper LJ. Identifying candidate allogeneic NK-cell donors for hematopoietic stem-cell transplantation based on functional phenotype. Leukemia 24(5):1059-62, 5/2010. e-Pub 2/2010. PMID: 20164852.
37. Hackett PB, Largaespada DA, Cooper LJ. A Transposon and Transposase System for Human Application. Mol Ther 18(4):674-83, 4/2010. e-Pub 1/2010. PMCID: PMC2862530.
38. Micklethwaite KP, Savoldo B, Hanley PJ, Leen AM, Demmler-Harrison GJ, Cooper LJ, Liu H, Gee AP, Shpall EJ, Rooney CM, Heslop HE, Brenner MK, Bollard CM, Dotti G. Derivation of human T lymphocytes from cord blood and peripheral blood with antiviral and antileukemic specificity from a single citation culture as protection against infection and relapse after stem cell transplantation. Blood 115(13):2695-703, 4/2010. PMID: 20110422.
39. Manuri PB, Wilson MH, Maiti SN, Mi T, Singh H, Olivares S, Dawson MJ, Huls H, Lee DA, Rao PH, Kaminski JM, Nakazawa Y, Gottschalk S, Kebriaei P, Shpall EJ, Champlin RE, Cooper LJ. piggyBac transposon/transposase system to generate CD19-specific T cells for the treatment of B-lineage malignancies. Hum Gene Ther 21(4):427-37, 4/2010. PMID: 19905893.
40. Jena B, Dotti G, Cooper LJ. Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor. Blood 116(7):1035-1044, 2010. e-Pub 5/2010. PMID: 20439624.
41. Cooper LJ. New Approaches to Allogeneic Hematopoietic Stem-Cell Transplantation in Pediatric Cancers. Curr Oncol Rep 11(6):423-30, 11/2009. PMID: 19840519.
42. Galvan DL, Nakazawa Y, Kaja A, Kettlun C, Cooper LJ, Rooney CM, Wilson MH. Genome-wide Mapping of PiggyBac Transposon Integrations in Primary Human T Cells. J Immunother, 9/2009. e-Pub 9/2009. PMID: 19752750.
43. Cooper LJ. Persuading natural killer cells to eliminate bad B cells. Clin Cancer Res 15(15):4790-1, 8/2009. e-Pub 7/2009. PMCID: PMC2730884.
44. Dotti G, Tian M, Savoldo B, Najjar A, Cooper LJ, Jackson J, Smith A, Mawlawi O, Uthamanthil R, Borne A, Brammer D, Paolillo V, Alauddin M, Gonzalez C, Steiner D, Decker WK, Marini F, Kornblau S, Bollard CM, Shpall EJ, Gelovani JG. Repetitive noninvasive monitoring of HSV1-tk-expressing T cells intravenously infused into nonhuman primates using positron emission tomography and computed tomography with 18F-FEAU. Mol Imaging 8(4):230-7, Jul-Aug, 7/2009. PMID: 19728977.
45. Dossett ML, Teague RM, Schmitt TM, Tan X, Cooper LJ, Pinzon C, Greenberg PD. Adoptive immunotherapy of disseminated leukemia with TCR-transduced, CD8+ T cells expressing a known endogenous TCR. Mol Ther 4(4):742-9, 4/2009. e-Pub 2/2009. PMCID: PMC2730935.
46. Capitini CM, Cooper LJ, Egeler RM, Handgretinger R, Locatelli F, Sondel PM, Mackall CL. Highlights of the First International "Immunotherapy in Pediatric Oncology: Progress and Challenges" Meeting. J Pediatr Hematol Oncol 31(4):227-44, 4/2009. PMCID: PMC2714285.
47. Singh H, Najjar AM, Olivares S, Nishii R, Mukhopadhyay U, Alauddin M, Manuri PR, Huls H, Lee DA, Dotti G, Bollard C, Simmons PJ, Shpall EJ, Champlin RE, Gelovani JG, Cooper LJ. PET Imaging of T Cells Derived from Umbilical Cord Blood. Leukemia 23(3):620-622, 3/2009. e-Pub 10/2008. PMID: 18830258.
48. Pulsipher MA, Bader P, Klingebiel T, Cooper LJ. Allogeneic Transplantation for Pediatric Acute Lymphoblastic Leukemia: The Emerging Role of Peritransplantation Minimal Residual Disease/Chimerism Monitoring and Novel Chemotherapeutic, Molecular, and Immune Approaches Aimed at Preventing Relapse. Biol Blood Marrow Transplant 15(1):62-71, 1/2009. PMID: 19147081.
49. Rabinovich BA, Ye Y, Etto T, Chen JQ, Levitsky HI, Overwijk WW, Cooper LJ, Gelovani J, Hwu P. Visualizing fewer than 10 mouse T cells with an enhanced firefly luciferase in immunocompetent mouse models of cancer. Proc Natl Acad Sci U S A 105(38):14342-6, 9/23/2008. e-Pub 9/15/2008. PMCID: PMC2567214.
50. Bollard CM, Cooper LJ, Heslop HE. Immunotherapy targeting EBV-expressing lymphoproliferative diseases. Best Pract Res Clin Haematol 21(3):405-420, 9/2008. PMCID: PMC2610025.
51. Singh H, Manuri PR, Olivares S, Dara N, Dawson MJ, Huls H, Hackett PB, Kohn DB, Shpall EJ, Champlin RE, Cooper LJ. Redirecting specificity of T-cell populations for CD19 using the Sleeping Beauty system. Cancer Res 68(8):2961-71, 4/2008. PMCID: PMC2424272.
52. Komanduri KV, St John LS, de Lima M, McMannis J, Rosinski S, McNiece I, Bryan SG, Kaur I, Martin S, Wieder ED, Worth L, Cooper LJ, Petropoulos D, Molldrem JJ, Champlin RE, Shpall EJ. Delayed immune reconstitution after cord blood transplantation is characterized by impaired thymopoiesis and late memory T-cell skewing. Blood 110(13):4543-51, 12/2007. e-Pub 8/2007. PMCID: PMC2234787.
53. Numbenjapon T, Serrano LM, Chang WC, Forman SJ, Jensen MC, Cooper LJ. Antigen-independent and antigen-dependent methods to numerically expand CD19-specific CD8+ T cells. Exp Hematol 35(7):1083-90, 7/2007. PMID: 17588477.
54. Singh H, Serrano LM, Pfeiffer T, Olivares S, McNamara G, Smith DD, Al-Kadhimi Z, Forman SJ, Gillies SD, Jensen MC, Colcher D, Raubitschek R, Cooper LJ. Combining adoptive cellular and immunocytokine therapies to improve treatment of B lineage malignancy. Cancer Res 67(6):2872-80, 3/2007. PMID: 17363611.
55. DiGiusto DL, Cooper LJ. Preparing clinical grade Ag-specific T cells for adoptive immunotherapy trials. Cytotherapy 9(7):613-29, 2007. PMCID: PMC2238678.
56. Kowolik CM, Topp MS, Gonzalez S, Pfeiffer T, Olivares S, Gonzalez N, Smith DD, Forman SJ, Jensen MC, Cooper LJN. CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and anti-tumor efficacy of adoptively transferred T cells. Cancer Res 66(22):10995-11004, 11/2006. PMID: 17108138.
57. Numbenjapon T, Serrano LM, Singh H, Kowolik CM, Olivares S, Gonzalez N, Chang WC, Forman SJ, Jensen MC, Cooper LJ. Characterization of an artificial antigen presenting cell to propagate cytolytic CD19-specific T cells. Leukemia 20(10):1889-92, 10/2006. PMID: 17041638.
58. Serrano LM, Pfeiffer T, Olivares S, Numbenjapon T, Bennitt J, Kim D, Smith D, McNamara G, Al-Kadhimi Z, Rosenthal J, Forman SJ Jensen MC, Cooper LJN. Differentiation of naive cord-blood T cells into CD19-specific cytolytic effectors for posttransplantation adoptive immunotherapy. Blood 107(7):2643-53, 4/2006. e-Pub 12/2005. PMCID: PMC1895371.
59. Cooper LJN, Ausubel L, Gutierrez M, Stephan S, Shakeley R, Olivares S, Serrano L, Burton L, Jensen M, Forman S, DiGiusto D. Manufacturing of gene-modified cytotoxic T lymphocytes for autologous cellular therapy for lymphoma. Cytotherapy 8(2):105-117, 2006. PMID: 16698684.
60. Morris K, Castanotto D, Al-Kadhimi Z, Jensen M, Rossi J, Cooper LJ. Enhancing siRNA effects in T cells for adoptive immunotherapy. Hematology 10(6):461-67, 12/2005. PMID: 16321811.
61. Vishwanath RP, Brown CE, Wagner JR, Meechoovet HB, Naranjo A, Wright CL, Olivares S, Qian D, Cooper LJ, Jensen MC. A quantitative high-throughput chemotaxis assay using bioluminescent reporter cells. J Immunol Methods 302(1-2):78-89, 7/2005. PMID: 15987642.
62. Gonzalez S, Castanotto D, Li H, Olivares S, Jensen MC, Forman SJ, Rossi JJ, Cooper LJ. Amplification of RNAi-targeting HLA mRNAs. Mol Ther 11(5):811-18, 5/2005. PMID: 15851019.
63. Brown CE, Wright CL, Naranjo A, Vishwanath RP, Chang WC, Olivares S, Wagner JR, Bruins L, Raubitschek A, Cooper LJ, Jensen MC. Biophotonic cytotoxicity assay for high-throughput screening of cytolytic killing. J Immunol Methods 297(1-2):39-52, 2/2005. e-Pub 1/22/2005. PMID: 15777929.
64. Cooper LJ, Al-Kadhimi Z, Serrano LM Pfeiffer T, Olivares S, Castro A, Chang WC, Gonzalez S, Forman SJ, Jensen MC. Enhanced antilymphoma efficacy of CD19-redirected influenza MP1-specific CTL's by co-transfer of T cells modified to present influenza MP1. Blood 105(4):1622-31, 2/2005. e-Pub 10/2004. PMID: 15507526.
65. Kahlon KS, Brown C, Cooper LJ, Raubitschek A, Forman SJ, Jensen MC. Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells. Cancer Res 64(24):9160-6, 12/2004. PMID: 15604287.
66. Cooper LJ, Al-Kadhimi Z, DiGiusto D, Kalos M, Colcher D, Raubitschek A, Forman SJ, Jensen MC. Development and application of CD19-specific T cells for adoptive immunotherapy of B cell malignancies. Blood Cells Mol Dis 33(1):83-89, Jul-Aug, 7/2004. PMID: 15223016.
67. Cooper LJ, Topp MS, Pinzon C, Plavec I, Jensen MC, Riddell SR, Greenberg PD. Enhanced transgene expression in quiescent and activated human CD8+ T cells. Hum Gene Ther 15(7):648-58, 7/2004. PMID: 15242525.
68. Cooper LJ, Topp MS, Serrano LM, Gonzalez S, Chang WC, Naranjo A, Wright C, Popplewell L, Raubitschek A, Forman SJ, Jensen MC. T cell clones can be rendered specific for CD19: toward the selective augmentation of the graft-versus-B-lineage leukemia effect. Blood 101(4):1637-44, 2/2003. e-Pub 10/2002. PMID: 12393484.
69. Jensen MC, Cooper LJ, Wu AM, Forman SJ, Raubitschek A. Engineered CD20-specific primary human cytotoxic T lymphocytes for targeting B-cell malignancy. Cytotherapy 5(2):131-8, 2003. PMID: 12745575.
70. Cooper LJ, Shannon KM, Loken MR, Weaver M, Stephens K, Sievers EL. Evidence that juvenile myelomonocytic leukemia can arise from a pluripotential stem cell. Blood 96(6):2310-13, 9/2000. PMID: 10979983.
71. Cooper LJ, Kalos M, Lewinsohn DA, Riddell SR, Greenberg PD. Transfer of specificity for human immunodeficiency virus type 1 into primary human T lymphocytes by introduction of T cell receptor genes. J Virol 74(17):8207-12, 9/2000. PMCID: PMC112357.
72. Crookston KP, Reiner AP, Cooper LJ, Sacher RA, Blajchman MA, Heddle NM. RBC T activation and hemolysis: Implications for pediatric transfusion management. Transfusion 40(7):801-12, 7/2000. PMID: 10924607.
73. Riddell SR, Warren EH, Gavin MA, Akatsuka Y, Lewinsohn D, Mutimer H, Cooper L, Topp MS, Bonini C, Greenberg PD. Immunotherapy of human viral and malignant diseases with genetically modified T cell clones. Cancer J Suppl 3:S250-58, 5/2000. PMID: 10874495.
74. Greenspan NS, Cooper LJ. Complementarity, specificity, and the nature of epitopes and paratopes in multivalent interactions. Immunol Today 16(5):226-30, 5/1995. PMID: 7540013.
75. Cooper LJ, Robertson D, Granzow R, Greenspan NS. Variable domain-identical antibodies exhibit IgG subclass-related differences in affinity and kinetic constants as determined by surface plasmon resonance. Mol Immunol 31(8):577-84, 6/1994. PMID: 7515151.
76. Cooper LJ, Shikhman AR, Glass DD, Kangisser D, Cunningham MW, Greenspan NS. Role of heavy chain constant domains in antibody-antigen interaction: apparent specificity differences among streptococcal IgG antibodies expressing identical variable domains. J Immunol 150(6):2231-42, 3/15/1993. PMID: 7680687.
77. Greenspan NS, Cooper LJ. Cooperative binding by mouse IgG3 antibodies: implications for functional affinity, effector function, and isotype restriction. Springer Semin Immunopathol 15(2-3):275-91, 1993. PMID: 8256202.
78. Schreiber JR, Cooper LJ, Diehn S, Patawaran M, Glass DD, Tosi MF, Greenspan NS. IgG subclass affects function of antibodies directed to the O-specific side chain of Pseudomonas aeruginosa LPS. J Infect Dis 167:221-26, 1993.
79. Greenspan NS, Cooper LJ. Intermolecular cooperativity: a clue to why mice have IgG3? Immunol Today 13(5):164-68, 5/1992. PMID: 1642754.
80. Cooper LJ, Schimenti JC, Glass DD, Greenspan NS. H chain C domains influence the strength of binding of IgG for streptococcal group A carbohydrate. J Immunol 146(8):2659-63, 4/15/1991. PMID: 1901882.
81. Greenspan NS, Dacek DA, Cooper LJ. Cooperative binding of two antibodies to independent antigens by an Fc-dependent mechanism. FASEB J 3:2203-07, 1989.
82. Greenspan NS, Dacek DA, Cooper LJ. Fc region-dependence of IgG3 anti-streptococcal group A carbohydrate antibody functional affinity. The effect of temperature. J Immunol 141:4276-82, 1988.

Invited Articles

1. Cooper LJ, Jena B, Bollard CM. Good T cells bad B cells. Blood 119(12):2700-2, 3/22/2012. e-Pub 3/2012. PMID: 22442331.
2. Cooper LJ. Adoptive cellular immunotherapy for childhood malignancies. Bone Marrow Transplant 41(2):183-92, 1/2008. e-Pub 11/19/2007. PMID: 18026145.
3. Grupp SA, Verneris M, Sondel PM, Cooper LJ. Immunotherapy for pediatric cancer. Biol Blood Marrow Transplant 14(1 Suppl 1):33-43, 1/2008. PMID: 18162219.
4. Gress RE, Komanduri KV, Einsele H, Cooper LJ. Lymphoid reconstruction and vaccines. Biol Blood Marrow Transplant 13(1 Suppl 1):1083-90, 1/2007. PMCID: PMC1858644.
5. Cooper LJ. Long Live T Cells. Blood 105(1):8-9, 2005.
6. Cooper LJ, Kalos M, DiGiusto D, Brown C, Forman SJ, Raubitschek A, Jensen MC. T cell genetic modification for re-directed tumor recognition. Cancer Chemother Biol Response Modif 22:293-324, 2005. PMID: 16110618.
Other Articles
1. Ji, Lei, Liu, Shpall, Kebriaei,Champlin,Berry,Cooper. Bayesiancontinual reassessment method for dose-finding trials infusing T cells with limited sample size. Journal of Biopharmaceutical Statistics, 2012.
2. Cooper LJ. Persuading natural killer cells to eliminate bad B cells. Clin Cancer Res 15(15):4790-1, 8/1/2009. e-Pub 7/28/2009. PMCID: PMC2730884.
3. Capitini CM, Cooper LJ, Egeler RM, Handgretinger R, Locatelli F, Sondel PM, Mackall CL. Highlights of the First International Immunotherapy in Pediatric Oncology: Progress and Challenges Meeting. J Pediatr Hematol Oncol 31(4):227-44, 4/2009. PMCID: PMC2714285.
4. Cooper LJN. Test-driving CARs. Blood 112(6):2261-71, 9/2008. PMID: 18779394.

Abstracts

1. Keating, Michael, Cooper, Laurence. Is Chronic Lymphocytic Leukemia Still Incurable. Poster presentation at 2012 American Society of Hematology meeting in Atlanta, Georgia, 12/2012.
2. Phatarpekar, Prasad, Lee, Dean A, Cooper, Laurence. Lymphocytes, Lymphocyte Activation and Immunodeficiency, including HIV and other infections. Poster presentation at 2012 American Society of Hematology meeting in Atlanta, Georgia, 12/2012.
3. Kalos, Michael, Cooper, Laurence. Sustained Functional T cell Persistence and B Cell Aplasia Following CD19-Targeting adaoptive T Cell Immunotherapy for Relapsed, Refractory CD19+ Malignacy. Poster presentation at 2012 American Society of Hematology Atlanta, Georgia (#( #49948)), 12/2012.
4. Ang SO, Maiti SN, Moriarity B, Andrews K, Ossowski M, Tzeng K, Talbot R, Kellar D, Huls H, Kebriaei P, Kelly S, Shpall E, Largaespada DA, Champlin R, Hackett PB, Cooper LJN. Assessing Sleeping Beauty Transpositions for T-cell Immunotherapy by Supercomputer-based High-Throughput Profiling of Integration Events. Oral Presentation Session I, 2012 BMT Tandem Meetings, American Society for Blood and Marrow Transplantation, San Diego, CA (#43), 2/2012.
5. Ang SO, Maiti SN, Hartline C, Olivares S, Huls H, Champlin R, Cooper LJN. Avoiding the need for clinical-grade OKT3: Ex vivo expansion of T cells using artificial antigen presenting cells genetically modified to cross-link CD3. Poster Presentation at the 2012 BMT Tandem Meeting, San Diego, CA (#150404), 2/2012.
6. Singh H, Figliola M, Dawson M, Zhang L, Yang G, Huls H, Kelly S, Kebriaei P, Champlin R, Cooper LJN. Naďve CD19-specific T cells exhibit superior proliferation and potential for adoptive immunotherapy. Poster presentation at the 2012 BMT Tandem Meeting, San Diego, CA (#287), 2/2012.
7. Somanchi S, Somanchi A, Cooper LJN, Lee DA. Re-directing Homing of Natural Killer Cells Through Trogocytosis: Application In Adoptive Immunotherapy. Presented at the 2012 Keystone Symposia: Chemokines and Leukocyte Trafficking in Homeostasis and Inflamation, 1/2012.
8. Maiti S, Rao P, Jue Y, Mutani A, Dawson M, Figliola M, Yang G, Kellar D, Ang S, Olivares S, Huls H, Singh H, Manuri P, Jena B, Jin Z, Hackett P, Lee DA, Kebriaei P, Champlin R, Cooper LJN. Sleeping Beauty transposition to introduce a chimeric antigen receptor for human application. ASGCT 14th Annual Meeting, May 16-19, 2012 in Philadelphia, PA, 2012.
9. Ang S, Maiti S, Moriarity B, Ossowski M, Andrews K, Tzeng K, Talbot R, Kellar D, Huls H, Kebriaei P, Largaespada D, Champlin R, Hackett P, Cooper L. Assessing Potential Genotoxicity of Sleeping Beauty Transposition Events in T-Cell Immunotherapy by Supercomputer-based High Throughput Profiling. Presented at the American Society of Hematology 53rd Annual Meeting and Exposition, San Diego, CA (#4174), 12/2011.
10. Singh H, Huls H, Champlin R, Kebriaei P, Cooper LJN. Sleeping Beauty: Awaking T cells to recognize tumor cells. Presented at the 4th International Symposium on Translational Cancer Research Cancer Prevention, Udaipur, Rajasthan State, India, 12/2011.
11. Ang S, Maiti S, Moriarity B, Ossowski M, Andrews K, Tzeng K, Talbot R, Kellar D, Huls H, Kebriaei P, Largaespada D, Champlin R, Hackett P, Cooper L. Assessing Potential Genotoxicity of Sleeping Beauty Transposition Events in T-Cell Immunotherapy by Supercomputer-based High Throughput Profiling. Presented at the CPRIT Innovations in Cancer Prevention and Research Conference, Austin, TX (#143), 11/2011.
12. Cooper LJ. Genetically engineered receptors in adoptive cell therapies. Invited Presentation at the Society of Immunotherapy of Cancer (SITC) 26th Annual Meeting, Bethesda, MD (#1217124), 11/2011.
13. Sjaj M, Li S, Xing D, Lee D, Cooper L, TZou B, Li S, Robinson S, Yang H, Parmar S, Champlin R, Bollard C, Shpall E. Antigen Presenting Cell-Mediated Ex Vivo Expansion of Human Cord Blood Natural Killer Cells for Hematologic Malignancies. Presented at the World Cord Blood Congress III Cord Blood Transplantation and Immunobiology of Haematopoietic Stem Cell Transplant, Rome, Italy, 10/2011.
14. Liu Y, Wu H-W, Sheard MA, Sposto R, Cooper LJN, Lee DA, Seeger RC. Growth and Activation of Human Natural Killer Cells from Peripheral Blood for Neuroblastoma Immunotherapy. Oral Presentation at the 43rd Congress of the International Society of Paediatric Oncology (SIOP), Auckland, New Zealand, 10/2011.
15. Manuri PR, Roszik J, Olivares S, Huls H, Lee DA, Shpall EJ, Champlin RE, Kontoyiannis DP, Cooper LJN. Redirected Specificity of T cells to Target "Aspergillus". Presented at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) Meeting, Chicago, IL, 9/2011.
16. Ang SO, Hartline C, Mi T, Maiti SN, Jackson GW, Hul H, Shpall E, Lee DA, Champlin RE, Cooper LJN. Cancer Immunotherapy − Emphasis on Adoptive T Cell Transfer. Oral Presentation at the 14th Annual Meeting of the American Society of Gene & Cell Therapy, Seattle, WA (#353), 5/2011.
17. Kellar DL, Ang S, Olivares S, Huls H and Cooper LJN. CD56-specific T cells can distinguish between allogeneic and autologous CD56+ targets. Oral Presentation at the 14th Annual Meeting of the American Society of Gene & Cell Therapy, Seattle, WA (#500), 5/2011.
18. Torikai H, Reik A, Soldner F, Yuen C, Zhou Y, Kellar D, Huls H, Warren EH, Tykodi SS, Holmes MC, Rebar EJ, Lee DA, Champlin RE, Gregory PD, Jaenisch R and Cooper LJN. Disruption of HLA Expression To Enable Allogeneic Cells To Escape Immune Recognition. Oral Presentation at the 14th Annual Meeting of the American Society of Gene & Cell Therapy, Seattle, WA (#350568), 5/2011.
19. Oliveira SN, Giannoni F, Hardee CL, Sahaghian A, Cooper LJ, Kohn DB. Gene transfer to hematopoietic stem/progenitor cells as a novel approach for immunotherapy against B-lineage malignancies: in vivo xenograft model. Presented at the 53rd American Society of Hematology Annual Meeting and Exposition, San Diego, CA, 5/2011.
20. Ang SO, Hartline C, Mi T, Maiti SN, Jackson GW, Hul H, Shpall E, Lee DA, Champlin RE and Cooper LJN. Generating a Chimeric Antigen Receptor to Redirect T-cell Specificity After Infusion. Oral Presentation at the 14th Annual Meeting of the American Society of Gene & Cell Therapy, Seattle, WA (#353), 5/2011.
21. Senyukov V, Denman CJ, Cooper LJN, Lee DA. IL-21 has an anti-apoptotic effect on NK cells during activation. Presented at the 14th Annual Meeting of the American Society of Gene & Cell Therapy, Seattle, WA (#350300), 5/2011.
22. Caruso HG, Ang S, Harjeet SS, Simon O, and Cooper LJN. T Cells Genetically Modified To Express Chimeric Antigen Receptor Specific for EGFR for Glioma. Poster Presentation at the 14th Annual Meeting of the American Society of Gene & Cell Therapy, Seattle, WA (#234), 5/2011.
23. Deniger DC, Singh H, Huls H, Olivares S, Cooper LJN. Targeting B-Cell Malignancies With Chimeric Antigen Receptor-Modified Gamma Delta T Cells. Presented at the 14th Annual Meeting of the American Society of Gene & Cell Therapy, Seattle, WA (#224), 5/2011.
24. Maiti S, Zhang M, Bernatchez C, Torikai H, Kellar D, Gibbons H, Hernandez J, Andersson H, Huls H, Lee DA, Hwu P, Radvanyi L, Cooper LJN. Digital Multiplexed Quantification of both T-cell Receptor β-chain and α-chain Diversity in T cells using the Nanostring nCounter Assay System. Presented at the American Society for Blood Marrow Transplantation, 2011 BMT Tandem Meetings, Honolulu, HI, 2/2011.
25. Torikai H, Reik A, Yuen C, Zhou Y, Kellar D, Huls H, Warren EH, Tykodi SS, Gregory PD, Holmes MC, Rebar EJ, Lee DA, Champlin RE, Bonini C, Cooper LJN. Genetic reprogramming and editing of T cells using the Sleeping Beauty system and designer zinc finger nucleases. Oral Presentation at the American Society of Blood Marrow Transplantation, 2011 BMT Tandem Meeting, Honolulu, HI, 2/2011.
26. Phatarpekar P, Zhu S, Denman CJ, Nguyen-Jackson N, Stephanie S, Watowich S, Cooper LJN, Lee DA. STAT3 Activation Promotes NK Cell Proliferation, NKG2D Expression, and NK Cell Antitumor Activity. Keystone Symposium on NK and NKT Cell Biology, Breckenridge, CO, 1/2011.
27. Cooper LJ, Serrano LM, Al-Kadhimi Z, Olivares S, Gonzalez S, Pfeiffer T, Rosenthal J, Forman SJ, Jensen M. Cord blood-derived T cells can be genetically engineered to be B-lineage all-specific: Towards adoptive immunotherapy after umbilical cord blood transplantation. 46th Annual Meeting of the American Society of Hematology, San Diego, CA (#48), 12/2004.
28. Cooper LJ, Gonzalez S, Castanotto D, Li H, Jensen M, Forman S, Rossi J. Titration of siRNA expression in human T cells. 6th Annual Meeting of the American Society of Gene Therapy, Washington, DC (#450395), 6/2003.
29. Cooper LJ, Topp MS, Raubitschek A, Popplewell L, Forman SJ, Jensen MC. Human cytolytic T cell clones genetically modified to be CD19-specific can target B-lineage leukemia cells independent of adhesion molecule expression. 44th Annual Meeting of the American Society of Hematology, Philadelphia, PA (#submission #3998; publication #121), 12/2002.
30. Cooper LJ, Pinzon C, Plavec I, Topp MS, Riddell SR, Greenberg PD. Maintaining retroviral gene expression in quiescent primary human CD8+ T cells. 5th Annual Meeting American Society of Gene Therapy, Boston, MA (#Molecular Therapy 5(5) May 2002#1291), 6/2002.

Book Chapters

1. Cooper, L J.N., Heslop, Helen E. Adoptive cellular and gene therapy. In: Hematological malignancies in Children. World of Scientific Publishing Co. 2012, 2012.
2. Laurence JN, Heslop H. Adoptive Cellular and Gene Therapy. In: Hematological Malignancies in Children, Adolescents and Young Adults. Ed(s) M Cairo, S Perkins, 2010.
3. Riddell SR, Warren EH, Lewinsohn D, Mutimer H, Topp M, Cooper LJ, de Freis R, Greenberg PD. Application of T cell immunotherapy for human viral and malignant diseases. In: Therapeutic Vaccination Strategies. Walden P, Sterry W, Hennekes H (Eds): Springer-Verlag, Berlin, 53-73, 2000.
4. Greenspan NS and Cooper LJ. Implications of cooperativity and dimensional complexity for immunological recognition. In: Theoretical and Experimental Insights into Immunology. Perelson AS, Weisbuch G (EDS): Springer-Verlag, Berlin, 263-278, 1992.
5. Torikai H, Moyes JS, Cooper LJN. Engineering Immune Cells for Cancer Therapy. In: Engineering in translational Medicine. Submitted.

Books (edited and written)

1. Bast RC, Markman M, Hawk, E. Ed(s) L Cooper, L Kwak. Immunotherapy and Translational Cancer Research, 2011.
2. Bast RC, Markman M, and Hawk E. Ed(s) L Cooper, L Kwak. Introduction to Translational Cancer Research. Wiley Blackwell, 2011.

Grant & Contract Support

Title: Specific Targets for Therapy of Patients with Chronic Lymphocytic Leukemia
Funding Source: Leukemia and Lymphoma Society
Role: Principal Investigator
Duration: 10/1/2013 - 9/30/2018
 
Title: Aptamer-targeted off-the-shelf T cells
Funding Source: Biomedical Advanced Research and Development Authority
Role: Principal Investigator
Duration: 7/1/2013 - 7/1/2018
 
Title: Targeted T-cell therapy for Brain Tumors
Funding Source: Alex's Lemonade Stand
Role: Principal Investigator
Duration: 7/1/2013 - 6/30/2015
 
Title: PQD1: Modulating selective pressure of engineered T cells to improve therapy
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 6/20/2013 - 6/20/2017
 
Title: Single-Cell Biomarkers of Clinical-Grade T cells and NK Cells to Optimize Tumor Immunotherapy
Funding Source: Cancer Prevention & Research Institute of Texas (CPRIT)
Role: Co-Principal Investigator
Principal Investigator: Navin Varadarajan
Duration: 9/2012 - 8/31/2017
 
Title: Stability and potency of LAP+FOXP3+ Tregs as novel cell therapy for GVHD
Funding Source: NIH/NCI
Role: Co-Investigator
Principal Investigator: Dat Tran
Duration: 3/22/2012 - 3/22/2016
 
Title: T-cell Therapy After Hematopoietic Stem Cell Transplantation
Funding Source: Cancer Prevention & Research Institute of Texas (CPRIT)
Role: Principal Investigator
Duration: 12/1/2011 - 11/30/2014

Last updated: 7/16/2013